Mbx biosciences appoints andreas moraitis, m.d., as senior vice president of clinical development

Carmel, ind., june 23, 2025 (globe newswire) -- mbx biosciences, inc. (nasdaq: mbx), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of andreas moraitis, m.d.
MBX Ratings Summary
MBX Quant Ranking